IBRX - ImmunityBio - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

1.902B

Cash

45.95M

Avg Qtr Burn

-83.85M

Short % of Float

44.57%

Insider Ownership

72.58%

Institutional Own.

10.66%

Qtr Updated

06/30/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Anktiva (N-803) Details Bladder cancer, Cancer	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PD-L1 t-haNK Details Pancreatic cancer, Cancer	Phase 2/3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
hAd5-COVID-19 Details Vaccine, COVID-19	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
N-803 (Anktiva), haNK and Avelumab Details Metastatic merkel cell carcinoma, Insomnia, Mood disorders, Liver transplant, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Anktiva (N-803) + KEYTRUDA Details Non-small cell lung carcinoma, Cancer, Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.